Reduction in the incidence of myocardial infarction with sodium-glucose linked cotransporter-2 inhibitors: evident and plausible

Cardiovasc Diabetol. 2019 Jan 11;18(1):6. doi: 10.1186/s12933-019-0812-6.

Authors

Richard E Gilbert¹, Kim A Connelly²

Affiliations

¹ Division of Endocrinology, St. Michael's Hospital, 30 Bond Street, Toronto, ON, M5B 1W8, Canada. richard.gilbert@utoronto.ca.
² Division of Cardiology, St. Michael's Hospital, 30 Bond Street, Toronto, ON, M5B 1W8, Canada.

No abstract available

Keywords: Cardiovascular outcome trials; Myocardial infarction; Sodium–glucose linked cotransporter-2; Stroke.

MeSH terms

Animals
Diabetes Mellitus, Type 2 / drug therapy*
Diabetes Mellitus, Type 2 / epidemiology
Diabetes Mellitus, Type 2 / metabolism
Evidence-Based Medicine
Humans
Incidence
Myocardial Infarction / epidemiology
Myocardial Infarction / metabolism
Myocardial Infarction / prevention & control*
Protective Factors
Risk Assessment
Risk Factors
Sodium-Glucose Transporter 2 / drug effects*
Sodium-Glucose Transporter 2 / metabolism
Sodium-Glucose Transporter 2 Inhibitors / therapeutic use*
Treatment Outcome

Substances

SLC5A2 protein, human
Sodium-Glucose Transporter 2
Sodium-Glucose Transporter 2 Inhibitors

Grants and funding

CIHR/Canada